The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors

Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Fangyuan, Zwinderman, Martijn R. H., Dekker, Frank J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017514/
https://www.ncbi.nlm.nih.gov/pubmed/29498635
http://dx.doi.org/10.3390/molecules23030551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017514/
https://www.ncbi.nlm.nih.gov/pubmed/29498635
http://dx.doi.org/10.3390/molecules23030551

Ejemplares similares